Novartis plots new Pluvicto filing timeline after waiting for overall survival results

No­var­tis said Thurs­day in a brief, five-sen­tence press re­lease that it plans to file for an ex­pand­ed la­bel for its prostate can­cer treat­ment Plu­vic­to in the sec­ond half of this year. The ex­pand­ed la­bel could po­ten­tial­ly make the ra­dio­phar­ma­ceu­ti­cal avail­able to two to three times the num­ber of pa­tients for whom it’s cur­rent­ly ap­proved.

The an­nounce­ment comes af­ter the phar­ma de­layed its fil­ing plans in Oc­to­ber be­cause at the time, the key study un­der­pin­ning its ap­pli­ca­tion did not show a clear sur­vival ben­e­fit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.